Stock market is in for 'choppy, bumpy ride' in 2026, strategist says. Why it pays to stay invested
Original Report
The market's worst days are often followed by the best days, according to JPMorgan Asset Management data. Investors who stay the course stand to gain the most.
Glass House Analysis
This story reflects the interconnected nature of modern economic systems, where developments in one sector inevitably affect others. Understanding these connections is essential for grasping how policy decisions and market movements translate into real-world outcomes for families, workers, and communities. The economy is not an abstract system of numbers—it's the sum total of decisions about who works, who prospers, and who struggles.
The implications extend beyond the immediate news cycle. Every economic development creates ripples that affect employment, prices, and opportunities in ways that may not be immediately visible but are deeply felt. By tracking these connections, we can better understand how the economy truly works—not as an abstract machine, but as a human system shaped by and shaping the lives of millions.
Enjoyed this analysis?
Get the Glass House Briefing every morning—market news that actually makes sense, delivered free to your inbox.
No spam. Unsubscribe anytime.
More Stories
Trump address live updates: President to speak on Iran tonight
Follow CNBC's live updates about President Donald Trump's remarks to the nation at 9 p.m. ET, his first primetime speech about the Iran war.
TSA shutdown: GOP leaders Thune and Johnson boost two-track approach to funding DHS
Funding for the Department of Homeland Security — including the TSA — lapsed in February, over Democratic concerns about the agency's immigration enforcement.
Novo VP Weighs In on Approval of Lilly’s Obesity Pill
Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly’s once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close." (Source:...
Novo’s New US Chief on Lilly’s Rival Weight-Loss Pill
Novo Nordisk Executive Vice President for US Operations Jamey Millar discusses the US approval of competitor Eli Lilly's obesity pill, the expansion of the GLP-1 category, and the rollout of a new...